Ovarian cancer
Results
Phase 2
This trial looked at adding a drug called vistusertib to paclitaxel chemotherapy for ovarian cancer that had come back.
It was for women who had ovarian cancer, primary peritoneal cancer or fallopian tube cancer. These cancers are treated in a similar way. When we use the term ovarian cancer in this summary, we are referring to all 3.
You pronounce vistusertib as vis-too-sir-tib.
Cancer Research UK supported this trial. It was open for people to join between 2015 and 2018. The team published the results in 2023.
Recruitment start: 1 January 2016
Recruitment end: 23 March 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Susana Banerjee
AstraZeneca
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
University of Glasgow
NHS Greater Glasgow and Clyde
This is Cancer Research UK trial number CRUKE/14/052.
Last reviewed: 7 November 2024
CRUK internal database number: 12661
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
